ReviewClinical drug investigation2013
Improving treatment adherence in your patients with schizophrenia: the STAY initiative.
Review in Clinical drug investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Predictors of long-term outcome of patients with schizophrenia in Africa: systematic review and meta-analysis.BMC public health · 2025Pooled it
- Strengthening the delivery of integrated physical health care for adults experiencing serious mental illness: a scoping review of interventions in mental health settings.Frontiers in health services · 2025Pooled it
- Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015Pooled it
- Assessing Usage and Usability of a Narrative-Based Psychoeducational Digital Intervention to Improve Medication Adherence Among Individuals With Schizophrenia in a Stable Phase: Mixed Methods Study.Journal of medical Internet research · 2026Trial
- Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.Journal of psychopharmacology (Oxford, England) · 2015Trial
- Schizophrenia Impacts and Treatment Priorities: Results of An Externally-Led Patient-Focused Drug Development Meeting Survey.Therapeutic innovation & regulatory science · 2026Article
- "Where are we on the Road Towards Family-focused Practice in Mental Healthcare?" - Perspectives from a Swedish/Norwegian Research Collaborative.Community mental health journal · 2026Article
- Review
- Internalised Stigma, Self-Esteem and Perceived Social Support as Psychosocial Predictors of Quality of Life in Adult Patients with Schizophrenia.Journal of clinical medicine · 2024Article
- The effects of the COVID-19 pandemic on hallucinations and delusions in youth at clinical high-risk for psychosis and outpatients with schizophrenia.European archives of psychiatry and clinical neuroscience · 2023Article
- Assessing evidence for seasonality of hospital admissions for schizophrenia in Queensland, Australia: a time series observational study.International journal of biometeorology · 2021Observational
- Observational
- Testing the hypothesis of subtypes of nonadherence in schizophrenia and schizoaffective disorder: A prospective study.World journal of psychiatry · 2020Article
- Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.Current opinion in HIV and AIDS · 2017Review
- Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.Psychopharmacology · 2017Article
- Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.Early intervention in psychiatry · 2016Review
- Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia.Drug design, development and therapy · 2016Review
- [Risk factors for treatment adherence in patients with schizophrenia: case-control study].The Pan African medical journal · 2015Article
- Pharmacy switch of antipsychotic medications: patient's perspective.Annals of general psychiatry · 2015Article
- Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.The international journal of neuropsychopharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Partial and non-adherence to medication is a common problem in schizophrenia, leading to an increased risk of relapse, increased likelihood of hospitalization and poorer long-term outcomes. In contrast, continuous medication in the treatment of schizophrenia is associated with positive outcomes, including improved clinical status, improved quality of life and functioning, and reduced risk of relapse and rehospitalization. Strategies aimed at improving medication adherence are therefore key for patients to achieve their treatment goals. In an attempt to address the issues of partial/non-adherence to antipsychotic medication in schizophrenia, a group of psychiatrists convened to discuss and develop a set of principles aimed at helping patients adhere to their medication. These principles were then refined and developed into the STAY (the Six principles to improve Treatment Adherence in Your patients) initiative following presentation to a wider group of psychiatrists from across Europe. This manuscript summarizes these principles and explains the rationale for their selection. These principles are: (1) recognizing that most patients with schizophrenia are at risk of partial/non-adherence at some time during the course of their illness; (2) the benefits of a good therapeutic alliance for identifying potential adherence issues; (3) tailored treatment plans to meet an individual's needs, including the most suitable route of delivery of antipsychotic medication; (4) involving family/key persons in care and psychoeducation of the patient, assuming the patient agrees to this; (5) ensuring optimal effectiveness of care; and (6) ensuring continuity in the care of patients with schizophrenia. The application of these six principles should help to raise awareness of and address poor patient adherence, as well as generally improving care of patients with schizophrenia. In turn, this should lead to improved overall clinical outcomes for patients receiving long-term treatment for schizophrenia.
Indexed as
Identifiers
23288695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.